Sanara MedTech, Inc. (SMTI)

Over the past six months, Sanara MedTech announced it was evaluating strategic alternatives for its THP subsidiary. The company reported its second-quarter 2025 financial results, showing a 28% increase in net revenue but also a net loss. The stock experienced a notable decline in October 2025. Sanara MedTech issued its Q3 2025 earnings, reporting an EPS of $0.09, and discontinued its Tissue Health Plus segment, which caused the stock to dip. The shutdown of THP was noted as an event that would make the company's financials cleaner. Sanara MedTech's stock rose after securing an Innovative Technology Contract from Vizient for its BIASURGE® Advanced Surgical Solution. The company reported unaudited preliminary financial results for the fourth quarter and full year ended December 31, 2025, and introduced its financial guidance for the full year 2026. The share price was $20.74, representing a decline of 43.13% from February 5, 2025, and the latest closing stock price as of February 6, 2026, was $20.24.

Specific detailed information regarding the demand seasonality for Sanara MedTech, Inc.'s products and services is not readily available.

Sanara MedTech, Inc. (SMTI) is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound, and skin markets. The company operates within the healthcare sector, specifically in the medical equipment industry. Its major products include CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen; BIASURGE, a no-rinse irrigation solution; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft; and products in the Bone Fusion Segment such as ALLOCYTE, BiFORM, and ACTIGEN.

Sanara MedTech Inc. serves markets across North America, Europe, Latin America, and Asia Pacific through direct sales teams and distributor partnerships. Its headquarters are located in Irvine, California. Its subsidiary, Tissue Health Plus (THP), launched a pilot program for value-based wound care services with a provider group operating across six states in the US.

Sanara MedTech's brand reputation has been influenced by challenges and strategic advancements. The decision to discontinue its Tissue Health Plus (THP) subsidiary could have negatively impacted its reputation in the short term, but was aimed at streamlining operations. Positive developments include product innovation, strategic partnerships such as the Vizient contract for BIASURGE, revenue growth in the surgical segment, and an industry standing where Sanara MedTech scored higher than 50% of companies evaluated by MarketBeat.

Sanara MedTech Inc. has a diverse ownership structure, including institutional, retail, and insider ownership. The company has 118 institutional owners and shareholders holding a total of 1,346,234 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, and State Street Corp. Ron Nixon is identified as the largest shareholder and Executive Chairman, and Seth Yon, the current CEO, directly owns 1.01% of the company's shares.